Skip to main content
European Commission logo print header

Eliminating Uncertainty in Coronary Artery Disease

Resultado final

3.2 Regulatory Approval EU

Founded on deliverable 31 the subsequent focus is to apply for and achieve regulatory approval for the MedTrace solution in the EU in the form a CEmark as medical device of the software and the medical device part of the hardware

3.1 Clinical Study EU

"In order to approve the MedTrace solution as medical device, the company needs to carry out a minor clinical study using 15O-water in cardiac patients to prove safety and efficacy. Part of this study is to purchase already existing data from Amsterdam University Medical Centers from a recent similar clinical trial. In parallel the clinical study will be prepared (study protocol, site recruitment, clinical trial agreements and patient recruitment) End deliverable is ""last patient scanned""."


Initial Experience with routine 15O-water cardiac PET workflow

Autores: Susanne Hansen, Jeppe Madsen, Shakti Nicolai Johansen, Charlotte Jensen, Lone Winkler, Lars Gormsen and Lars Tolbod, ,
Publicado en: Journal of Nuclear Medicine, Issue May 2021, 62 (supplement 1), 2021, Page(s) 3001, ISSN 2047-2412
Editor: SNM

Cardiac viability PET using combined parametric 15O-water blood flow/18F-FDG metabolism compares well with 82Rb/18F-FDG

Autores: Mette Kjaerulff, Simon Madsen, Kirsten Bouchelouche, Lars Gormsen and Lars Tolbod
Publicado en: Journal of Nuclear Medicine, Issue May 2021, 62 (supplement 1), 2021, Page(s) 1632
Editor: SNMMI

Buscando datos de OpenAIRE...

Se ha producido un error en la búsqueda de datos de OpenAIRE

No hay resultados disponibles